Universal routine HPV vaccination for young girls in Uganda: A review of opportunities and potential obstacles

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Banura, Cecily ^a   Mirembe, Florence M ^a   Katahoire, Anne R ^a   Namujju, Proscovia B ^b,c   Mbidde, Edward K ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENCE; ADOLESCENT; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DRUG COST; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LAW; PATIENT EDUCATION; POLITICS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURVIVAL TIME; UGANDA; UTERINE CERVIX CANCER; VACCINATION;

EID: 84865645863     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-24     Document Type: Review

References (60)

1. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0 IARC Press, Lyon 2004
2. The Economist Intelligence Unit, Breakaway: The global burden of cancer-challenges and opportunities GlobalEconomicImpact, London/New York/Hong Kong 2009 http://www.livestrong.org/pdfs/
3. Chapter 2: The burden of HPV-related cancers. Parkin DM, Bray F, Vaccine 2006 24S3 3/11 S3/25
4. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J, JAMA 2001 285 2995 3002 10.1001/jama.285.23.2995 11410098
5. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA, Am J Epidemiol 2003 157 3 218 226 10.1093/aje/kwf180 12543621
6. Chapter 16: HPV vaccines in immunocompromised women and men. Palefsky JM, Gillison ML, Strickler HD, Vaccine 2006 24 Suppl 3 140 S146
7. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: a systematic review. Banura C, Mirembe MF, Katahoire RA, Namujju PB, Mbonye AK, Wabwire FM, BMC Infect Agents Cancer 2011 5 11
8. Cervical cancer as a priority for prevention in different regions: an evaluation using years of life lost. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF, Int J Cancer 2004 109 3 418 424 10.1002/ijc.11719 14961581
9. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. de Sanjosé S, Diaz M, Castellsagué X, Clifford R, Bruni L, Munoz N, Bosch FX, Lancet Infect Dis 2007 7 7 453 459 10.1016/S1473-3099(07)70158-5 17597569
10. Cross-protective efficacy of HPV 16/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by non-vaccine oncogenic HPV types: 4-year end of study analysis of the randomized, double-blind PATRICIA trial. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow S-N, Apter D, Kitchner H, Lancet Oncol 2012 13 1 100 110 10.1016/S1470-2045(11)70287-X 22075170
11. Chapter 4: Burden and management of non-cancerous HPV-related condition: HPV 6/11. Lacey CJN, Lowndes CM, Shah KV, Vaccine 2006 24 S3 3:/35 S3/41
12. Against which human papillomatypes shall we vaccinate and screen? International perspective. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Kerti SV, Meijer CJLM, Int J Cancer 2004 111 2 278 285 10.1002/ijc.20244 15197783
13. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. Strickler HD, Burk RD, Fazzari M, Anostos K, Minkkoff H, Massad LS, Hall S, Bacon M, Levine AM, Watts DH, Silverberg MJ, Xue X, Schlecht NF, Melnick S, Palefsky J, J Natl Cancer Inst 2005 97 577 586 10.1093/jnci/dji073 15840880
14. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM, Int J Cancer 2007 121 621 632 10.1002/ijc.22527 17405118
15. Estimates of the worldwide incidence of 25 major cancers in 1990. Parkin DM, Pisani P, Ferlay J, Int J Cancer 1999 80 827 841 10.1002/(SICI)1097- 0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P 10074914
16. Financing HPV vaccination in developing countries. Lancet T, Lancet 2011 377 9777 1544 21550467
17. Chapter 15: HPV vaccine use in developing countries. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F, Vaccine 2006 24 S3 3/132 S3139
18. Human papillomavirus vaccines WHO position paper. WHO, Weekly Epidemiol Record 2009 84 15 117 132
19. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, Cancer Incidence in 5 continents Vol. IX. IARC Scientific Publiation No. 160 IARC, Lyon 2008
20. WHO/ICO Information Centre, HPV and Cervical cancer 2012 HYPERLINK "http://www.who.int/hpvcentre/en/" http://www.who.int/hpvcentre/en/ Accessed February 2012
21. Trends in cancer incidence in Kyadondo County, Uganda 1960-97. Wabinga H, Parkin DM, Wabwire-Mangen F, Nambooze S, Br J Cancer 2000 82 1585 1592 10789729
22. Situation analysis for cervical cancer diagnosis and treatment in East, Central and Southern African countries. Chirenje ZM, Rusakaniko S, Kirumbi L, Ngwalle EW, Makuta-Tlebere P, Kaggwa S, Mpanju-Shumbusho W, Makoae L, Bull World Health Organ 2001 79 2 127 132 11242819
23. An assessment of readiness for introduction of the HPV vaccine in Uganda. Katahoire RA, Jitta J, Kivumbi G, Murokora D, Arube Wani J, Sui G, Arinaitwe L, Bingham A, Mugisha E, Tsu V, LaMontagne DS, Afr J Reprod Health 2008 12 3 159 172 19435020
24. Hospice Uganda: 1993-1998. Merriman A, J Pall Care 1999 15 50 52
25. Cancer survival in Kampala, Uganda. Gondos A, Brenner H, Wabinga H, Parkin D, Br J Cancer 2005 92 9 1808 122 10.1038/sj.bjc.6602540 15827554
26. HYPERLINK "http://www.avert.org/aids-uganda.htm" http://www.avert.org/aids-uganda.htm
27. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer registry match study. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA, Int J Cancer 2006 118 985 990 10.1002/ijc.21443 16106415
28. HIV infection among Ugandan women with cervical cancer: a retrospective study. Sekirime WK, Gray R, Gynecol Obstet Invest 2007 63 4 222 228 10.1159/000098197 17191009
29. Survival of cervix cancer patients in Kampala, Uganda: 1995-1997. Wabinga H, Ramanakumar A, Banura C, Luwaga A, Nambooze S, Parkin DM, Br J Cancer 2003 89 65 69 10.1038/sj.bjc.6601034 12838301
30. PATH/CHDC/UNEPI, HPV vaccination in Africa: Lessons learned from a pilot program in Uganda PATH, Seattle 2011
31. Gardasil access program. http://www.gardasilaccessprogram.org/x/ About%20GAP%20Fact%20Sheet%20FINAL(17).pdf
32. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle- income countries. LaMontagne DS, Barge S, Le TN, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO, Bull World Health Organ 2011 89 821 30B 10.2471/BLT.11.08986 22084528
33. PATH/UNEPI/CHDC, HPV demonstration project in Uganda: Results, lessons learned and recommendations PATH, Seattle 2010
34. Jitta J, Review of Child Days Plus Strategy CHDC, Kampala 2007
35. Mildmay Uganda, Annual Report 2010/11 Mildmay Uganda, Kampala 2011
36. World Bank, Indicators http://www.data.worldbank.org/indicators/
37. World Bank, Health expenditure, total (% GDP) http://data.worldbank.org/ indicators/
38. GOU, National Budget Framework Paper FY2010/11- FY2010/15 MOFPED, Kampala 2010
39. OAU, Abuja declaration on HIV/AIDS, Tuberculosis and other related infectious diseases, Abuja 2001 http://www.un.org/ga/aids/pdf/abuja-declaration. pdf
40. WHO, Commission for Macroeconomics and Health WHO, Geneva 2001
41. Health and economic outcomes of HPV 16, 18 vaccination in 72-GAVI-eligible countries. Goldie S, O'Shea M, Campos N, Diaz M, Sweet S, Kim S-Y, Vaccine 2008 26 4080 4093 10.1016/j.vaccine.2008.04.053 18550229
42. Population Reference Bureau data finder http://www.prb.org/datafinder. aspx
43. MOH/ICF/CDC/USAID/WHO/UBOS/UVRI, Uganda AIDS Indicator Survey 2011 preliminary report UBOS, Kampala 2012
44. Sexual behavior, knowledge and information sources of very young adolescents in four sub Saharan countries. Bankole A, Biddlecom A, Guiella G, Singh S, Zule E, Afr J Reprod Health 2007 11 28 43 10.2307/25549730 18458739
45. Neema S, Ahmed FH, Kibombo R, Bankole A, Adolescent sexual and reproductive health in Uganda: Results from 2004 national survey of adolescents: Occasional Report No. 25 Allan Guttmacher Institute, New York 2006
46. NRM, NRM manifesto 2011-2016, Kampala 2010
47. GOU, Public Health Act 1935 (Chapter 281) GOU, Kampala 2000
48. GOU, Local Government Act 1997 (Chapter 243) GOU, Kampala 1997
49. MOH, Health Sector Strategic Plan III (2010/11-2014/15) MOH, Kampala 2010
50. HYPERLINK "http://www.gavialliance.org" http://www. gavialliance.org
51. MOH/MOES, School Health Policy for Uganda: A healthy mind in a healthy body for better performance MOH, Kampala 2002
52. CIA World Fact book HYPERLINK "http://www.cia.gov/library/ publications/the-worl-factbook/geos/ug.html" http://www.cia.gov/library/ publications/the-worl-factbook/geos/ug.html
53. Human papillomavirus vaccine support HYPERLINK
54. MOH, Annual health sector performance report 2010/11 MOH, Kampala 2011
55. Quentin W, Watson-Jones D, Changalucha J, Hutubessey R, Edmunds J, Hayes R, Kapiga S, Terris-Prestholt F, Costs of delivering HPV vaccine to school girls in Tanzania [Abstract 05-05] 27th International Papillomavirus Conference and Clinical Workshop, Berlin 2011
56. UNICEF, Combatting antivaccination rumours: Lessons learned from case studies in East Africa UNICEF, Nairobi 2003
57. Musisi NB, Kasente D, Balihuta AM, Attendance patterns and causes of dropout in primary schools in Uganda: A case study of 16 schools Makerere University, Kampala 2003
58. IAVI/PATH, HPV vaccine adoption in developing countries: cost and financing issues PATH, Seattle 2007
59. Human papillomavirus vaccine policy and delivery in Latin America and the Carribean. Andrus J, Lewis M, Goldie S, Garcia P, Winkler J, Ruiz-Matus C, de Quadros CA, Vaccine 2008 26S 11 80 L87
60. Waisbord S, Larson H, Why invest in communication for immunization: Evidence and lessons learned JHU/UNICEF, Baltimore/New York 2005